助手标题
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
共[464]条 当前为第1条到20条[由于搜索限制,当前仅支持显示前5页数据]
 

相关语句
prostatic hyperplasia
Routine transurethral resection was performed due to benign prostatic hyperplasia with subvesical obstruction.
      
GYKI-16084 - (+)-(R)-2-{3-(benzo[1,4]dioxan-2-yl-methylamino)-1-propyl}-3(2H)-pyridazinone hydrochloride - is a new drug candidate for the treatment of benign prostatic hyperplasia.
      
Minimally invasive techniques for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: An up
      
Benign prostatic hyperplasia (BPH) primarily affects middle-aged and elderly men.
      
Urinary incontinence can result following surgical treatment of benign prostatic hyperplasia or prostate cancer and has a significant impact on quality of life.
      
It generally is thought that the beneficial effect of α1-adrenoceptor (AR) antagonists on lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia is caused mainly by relaxation of prostatic/urethral smooth muscle.
      
The role of urodynamics in the diagnosis and treatment of benign prostatic hyperplasia
      
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia
      
Medical therapy for benign prostatic hyperplasia (BPH) attempts to duplicate the known benefits of prostatectomy without the associated morbidity.
      
Throughout the past decade, several minimally invasive therapies for benign prostatic hyperplasia (BPH) have emerged to challenge transurethral prostatectomy (TURP) in efficacy and safety.
      
Laser therapy for the treatment of benign prostatic hyperplasia: A review
      
Laser therapies for the treatment of benign prostatic hyperplasia have progressed significantly over the past decade.
      
The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia
      
Although histologic changes of benign prostatic hyperplasia (BPH) begin in men when they are in their thirties, symptomatic BPH characterized by lower urinary tract symptoms (LUTS) typically do not develop for several decades.
      
Medical treatment for the symptoms of benign prostatic hyperplasia (BPH) consists of α blockers and 5-α -reductase inhibitors.
      
Phytotherapy for benign prostatic hyperplasia and lower urinary tract symptoms has been popular in Europe and is becoming increasingly popular in the United States.
      
Nevertheless, because serum PSA concentration, particularly when less than 10 ng/mL, reflects the presence of benign prostatic hyperplasia more often than cancer, there is a clear need for more specific prostate cancer markers.
      
The treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia recently has seen a large growth of minimally invasive technologies.
      
Lasers for lower urinary tract symptoms secondary to benign prostatic hyperplasia: When is the fuss worth it
      
In the recent past, several endoscopic procedures using laser technology have evolved for the treatment of benign prostatic hyperplasia.
      
 

首页上一页12345下一页尾页 

 
CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社